105 results
Page 4 of 6
SC TO-T
EX-99
35tie5j8
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
e29rmm5v2tj1vi0zr
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
0lt5 zbkv6s0ir7m
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
j5i 6ppb0
28 Apr 11
Key R&D Milestones and Strong Financials
12:00am
8-K
EX-99.1
1kd7omr0lmtfj9z krpr
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
k3e295 p5
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
eqvadvia
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
8-K
EX-99.1
7rn69j2aqudwd265y7iw
29 Apr 10
Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter
12:00am
8-K
EX-99.1
nmizt3hme
28 Jan 10
Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009
12:00am
8-K
EX-99.1
mjreyi rf
22 Oct 09
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
12:00am